A Breakthrough Therapies Pathway In Europe? Not Likely, Regulators Say

Drug companies looking for an FDA-style breakthrough therapies pathway in Europe shouldn’t hold their breath: the current European health care reimbursement landscape, regulators say, cannot support a breakthrough pathway.